eribulin + anlotinib

Eribulin + anlotinib is a combination therapy consisting of two small molecule drugs used primarily in the treatment of advanced or metastatic cancers, including HER2-negative metastatic breast cancer and retroperitoneal liposarcoma (RLPS). Eribulin mesylate is a non-taxane microtubule dynamics inhibitor that disrupts mitotic spindle formation, leading to cell cycle arrest and apoptosis. Anlotinib is a novel oral multi-target tyrosine kinase inhibitor that blocks angiogenesis and tumor growth by inhibiting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and c-Kit. The combination has demonstrated synergistic cytotoxicity in preclinical models, with enhanced anti-tumor effects compared to either agent alone. Clinical studies have shown promising efficacy with manageable toxicity profiles in heavily pretreated patients with HER2-negative metastatic breast cancer and RLPS[1][2][3].

Other names

eribulin mesylate + anlotinib hydrochlorideeribulin and anlotinib